Morand and colleagues review the validation of macrophage migration inhibitory factor as a therapeutic target in atherosclerosis and rheumatoid arthritis, and explore how emerging small-molecule inhibitors could address a possible mechanistic link between these diseases.
- Eric F. Morand
- Michelle Leech
- Jürgen Bernhagen